AKI Program
Acute Kidney Injury
Clinical Trial LaunchActive
Key Facts
About Keli Therapeutics
KELI Therapeutics is a private, pre-revenue biotech founded in 2017 and headquartered in Kaunas, Lithuania, with a presence in Berlin. The company is developing a diversified pipeline of autologous and allogeneic cell therapies, primarily for cartilage repair and inflammatory diseases, with its lead programs in pre-clinical and early clinical development. It recently secured a €2.5 million grant from the European Innovation Council to fund a clinical trial in Acute Kidney Injury, indicating external validation and non-dilutive funding. Leadership comprises experienced professionals in regenerative medicine, manufacturing, and clinical development.
View full company profileTherapeutic Areas
Other Acute Kidney Injury Drugs
| Drug | Company | Phase |
|---|---|---|
| VANADIS® (AKI) | CFM Pharma | Pre-clinical |
| ENT1 Inhibitor | RapaFusyn Pharmaceuticals | Preclinical |